CYTC going on this news:
CYTC Cytyc Announces Exclusive ThinPrep Pap Test Contract with Largest Private Labora
ory in The UK
Business Editors/Health/Medical Writers
BOXBOROUGH, Mass.--(BUSINESS WIRE)--Aug. 5, 2003--Cytyc
Corporation (Nasdaq:CYTC) today announced it has signed a five-year
exclusive contract with the British United Provident Association
(BUPA) to provide the ThinPrep(R) Pap Test to all patients in the BUPA
Hospital System. The BUPA National Cervical Cytology Screening
Service, based at BUPA Hospital Bristol, provides cervical screening
for 35 BUPA hospitals in the UK. BUPA is the leading independent
health and care organization in the UK.
After evaluating a range of available cervical screening
technologies, BUPA selected the ThinPrep Pap Test. "We are very
impressed with both the technology and reliability of the equipment
offered by Cytyc," said Sandie Foxall Smith, general manager of the
BUPA Hospital, Bristol. "The purpose of cervical screening is to
identify as many women as possible who have abnormalities whilst not
identifying women as being at risk when they have nothing wrong - this
technology is a step closer to achieving this ideal."
"We are very pleased with the recent successes in the adoption of
the ThinPrep Pap Test by sizeable screening programs in the United
Kingdom and Scotland," said Patrick J. Sullivan, Cytyc's chairman,
president, and chief executive officer. "We hope to build on this
momentum, should the UK National Health Service elect to adopt
liquid-based cytology."
The National Institute for Clinical Excellence (NICE) has been
evaluating the clinical and cost benefits of liquid-based cytology. A
preliminary report recommended the use of liquid-based cytology "as
the primary means of collecting samples in the cervical screening
programme in England and Wales." The NICE Final Appraisal
Determination is expected this month and final guidance to the UK's
National Health Service is currently scheduled for September of this
year.
In March of this year, Cytyc announced that the Scottish Cervical
Screening Programme had selected the ThinPrep Pap Test as the new
technology for total conversion of all cervical screening centers in
Scotland. The Scottish contract with Cytyc UK is for five years, with
a commitment to full conversion in Scotland by March 2004.
Cytyc Corporation designs, develops, manufactures, and markets the
ThinPrep(R) System for use in medical diagnostic applications
primarily focused on women's health. The ThinPrep System is widely
used for cervical cancer screening and is the platform from which the
Company has launched its expansion into breast cancer risk assessment
with the FirstCyte(TM) Breast Test. The ThinPrep System consists of
the ThinPrep(R) 2000 Processor, ThinPrep(R) 3000 Processor,
ThinPrep(R) Imaging System, and related reagents, filters, and other
supplies. Cytyc is traded on The Nasdaq Stock Market under the symbol
CYTC.
Cytyc and ThinPrep are registered trademarks of Cytyc Corporation.
FirstCyte is a trademark of Cytyc Corporation for which registration
has been applied.
Forward-looking statements in this press release are made pursuant
to the provisions of Section 21E of the Securities Exchange Act of
1934. Investors are cautioned that statements in this press release
which are not strictly historical statements, including, without
limitation, statements relating to the Company's financial condition,
operating results and future economic performance, and management's
expectations regarding future growth opportunities, product acceptance
and business strategy, constitute forward-looking statements. These
statements are based on current expectations, forecasts and
assumptions that are subject to risks and uncertainties, which could
cause actual outcomes and results to differ materially from those
statements. Risks and uncertainties include, among others, dependence
on key personnel and proprietary technology, uncertainty of product
development efforts, product acceptance, management of growth, risks
associated with competition and competitive pricing pressures, risks
associated with the FDA regulatory approval processes and any
healthcare reimbursement policies, risks associated with litigation,
and other risks detailed in the Company's filings with the Securities
and Exchange Commission, including under the heading "Certain Factors
Which May Affect Future Results" in its 2002 Annual Report on Form
10-K and its most recent Quarterly Report on Form 10-Q filed with the
Commission. The Company cautions readers not to place undue reliance
on any such forward-looking statements, which speak only as of the
date they were made. The Company disclaims any obligation to publicly
update or revise any such statements to reflect any change in Company
expectations or events, conditions, or circumstances on which any such
statements may be based, or that may affect the likelihood that actual
results will differ from those set forth in the forward-looking
statements.
--30--GK/bo*
CONTACT: Cytyc Corporation
Robert Bowen, Chief Financial Officer
Anne Rivers, Investor Relations
Jeff Keene, Healthcare Media
978/266-3010
www.cytyc.com
KEYWORD: MASSACHUSETTS UNITED KINGDOM INTERNATIONAL EUROPE
INDUSTRY KEYWORD: PHARMACEUTICAL MEDICAL MEDICAL DEVICES
SOURCE: Cytyc Corporation
Today's News On The Net - Business Wire's full file on the Internet
with Hyperlinks to your home page.
URL: businesswire.com
*** end of story *** |
